Publications

Add filters (0)

233 results

Viewing results for fatty

Type VI collagen is proportionally lower around airways and blood vessels in idiopathic pulmonary fibrosis.

November 1, 2026

Am J Physiol Cell Physiol

Abstract Type VI collagen (COL6) is a key extracellular matrix protein that supports matrix organization and cell-matrix interactions, yet its regulation in idiopathic pulmonary fibrosis (IPF) remains poorly understood. Here, we characterize COL6 gene expression, spatial localization, remodeling, and functional effects of COL6-derived fragments. Analysis of publicly available single-cell RNA sequencing data from 30 control subjects […]

Read publication

Non-invasive tests in metabolic dysfunction-associated steatotic liver disease: the LITMUS prospective multicentre diagnostic accuracy study.

October 31, 2026

Lancet

Abstract BACKGROUND The advent of regulatory-approved pharmacological treatments for metabolic dysfunction-associated steatotic liver disease (MASLD) calls for precise, non-invasive biomarkers that facilitate early diagnosis, support therapy selection, and aid clinical trial enrolment. The European multicentre LITMUS study aimed to evaluate the diagnostic performance of a broad range of non-invasive biomarkers for identifying patients with metabolic […]

Read publication

Endotrophin Measured by PRO-C6 as a Prognostic Biomarker for Liver-Related Events in Patients With Advanced Chronic Liver Disease.

September 1, 2026

Liver Int

Abstract BACKGROUND & AIMS Prognostic non-invasive tests for liver-related events in compensated cirrhosis are needed. Endotrophin, a fragment of type VI alpha 3 collagen involved in fibrosis and inflammation, has been associated with adverse outcomes in several chronic diseases. This study examined the association between baseline endotrophin levels, measured by nordicPRO-C6 (PRO-C6), and liver-related events […]

Read publication

Investigation of non-invasive tests for fibrosis diagnosis and prognostication of events in metabolic dysfunction-associated steatotic liver disease: A prospective study cohort.

September 1, 2026

Ann Hepatol

Abstract INTRODUCTION AND OBJECTIVES Risk stratification is important in the management of metabolic dysfunction-associated steatotic liver disease (MASLD) to prioritize monitoring and treatment resources. We evaluated whether non-invasive tests (NITs) can predict major adverse liver outcomes (MALOs) and diagnose advanced fibrosis in patients with MASLD. PATIENTS AND METHODS A prospective cohort of 270 patients with […]

Read publication

Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study.

August 1, 2026

Nat Med

Abstract There is a need for robust evaluations of noninvasive biomarkers for metabolic dysfunction-associated steatotic liver disease. This prospective multicenter study assessed the diagnostic accuracy of imaging (including liver stiffness measurement (LSM) using magnetic resonance elastography (MRE) and FibroScan (vibration-controlled transient elastography (VCTE)), serum biomarkers (including NIS2+) and composite scores (including Agile 3+ and Agile […]

Read publication

A framework and shared vocabulary to identify actionable protein biomarkers and enable optimal precision medicine: Myth-busting with unicorn biomarkers.

July 25, 2026

J Hepatol

Abstract Not all biomarkers are equal, and some arguably should not be classified as biomarkers at all. Despite an explosion in putative biomarker discoveries from high-throughput proteomic technologies, very few advance beyond initial excitement to become validated, clinically actionable tools. Most stall in a biomarker ‘valley of death’, where promising signals fail to meet robust […]

Read publication

Two-step care pathways for advanced MASLD in primary and hospital care: A multicenter study.

July 1, 2026

Hepatol Commun

Abstract BACKGROUND Early diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis may prevent liver-related morbidity and mortality. We investigated the effectiveness of multiple 2-step approaches for detecting at-risk advanced MASLD fibrosis, defined as a hierarchical clinical score comprising liver histology and VCTE depending on availability, in primary and hospital outpatient care. METHODS Patients at […]

Read publication